Reliability of Home Uroflowmetery Using a Disposable Digital Device

NCT ID: NCT02026674

Last Updated: 2014-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The FloRite™ device is a disposable urine flow meter, indicated for use in a home setting.

The device provides Urofowmetry measurements, similar to clinic's measurements. Clinic-based uroflowmetry has some flaws; the setting is artificial and often it is difficult to void at the desired moment. Moreover, a single measurement of the voided parameters is a poor representative of the patient condition due to high variability of the measured parameters. Performing multiple Urofowmetry measurements provides representative and more accurate results, in a more patient-friendly, cost effective method.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The FloRite™ product is a disposable urine flow meter. The patient needs to urinate into the device and at the end of urination the patient needs to disconnect a USB drive from the device, dispose the device's container and keep the USB drive that contains the test data.

Primary objectives:

• Usability evaluation of the FloRite™ system with LUTS patients.

Secondary objectives:

* Comparison of uroflowmetric parameters obtained using home disposable digital uroflowmetry device with standard clinic-based uroflowmetry.
* Evaluation of diurnal variations in uroflowmetric parameters obtained using home uroflowmetry

Primary outcome measures

• Successful use of FloRite™ system in LUTS patients, defined as:

* Successful unpacking and installation
* Successful understanding of the user manual
* Ability of the patients to operate the device as define by a successful test completion and data transmission
* Successful retrieval of the DOK
* Absence of:
* Device dropping down
* Urination outside the container
* Urination on the electronic unit

Secondary outcome measures:

• Comparison of uroflowmetric parameters as measured by

FloRite™ system and standard clinical uroflowmetry as defined by \[Time Frame: Days 0, 1, 6 and 7\]:

* Qmax - Max Flow Rate

• Evaluation of diurnal variations in uroflowmetric parameters obtained using home uroflowmetry as defined by \[Time Frame: Days 1, 6\]:
* Urine flow graph
* Tdelay - Delay time
* T100 - Voiding Time
* TQ - Flow Time
* Tqmax - Time to max Flow
* Qmax - Max Flow Rate
* Qave - Average Flow Rate
* Vcomp - Voided Volume Up to 30 completed patients

Inclusion criteria

* LUTS patients
* Male 18\<Age \<65
* Ability to speak, read and understand instructions
* Patient willing to sign an Informed Consent Exclusion criteria
* Mentally disabled patients
* Infectious diseases
* Catheterized patients
* Buried penis due to obesity The patients will be consented if found eligible. Prospective, self- controlled, interventional, clinical study

On the baseline visit, after eligibility is confirmed and after consenting the patients, the following steps will be taken:

* Standard clinical uroflowmetry
* Training how to use the system
* Unpacking and setting up the device (supervised by an observer)

The following day, the patient will perform home test with the FloRite™ system. Similar test will be conducted on Day 6 of the study.

The test results will be transferred either by e- mailing the data stored on the DOK or by bringing the DOK itself to the clinic on the 7th day.

On Day 7 of the study, the patients will be asked to return to the clinic for standard clinical uroflowmetry. In addition, the patient will fill a satisfaction questionnaire.

All the measurements must be standard and performed at around the same time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lower Urinary Tract Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FloRite

LUTS patients that used FloRite for home urine flow diagnostics.

Group Type EXPERIMENTAL

FloRite

Intervention Type DEVICE

Disposable home use urine flow meter.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FloRite

Disposable home use urine flow meter.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* LUTS patients
* Male 18\<Age \<65
* Ability to speak, read and understand instructions
* Patient willing to sign an Informed Consent

Exclusion Criteria

* Mentally disabled patients
* Infectious diseases
* Catheterized patients
* Buried penis due to obesity
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Flometrica Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ilan Leibovitch, Prof.

Role: PRINCIPAL_INVESTIGATOR

Meir Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

"Meir" Hospital

Kfar Saba, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zeev Cohen, M.Sc.

Role: CONTACT

+972-52-4471297

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ilan Leibovitch, Prof.

Role: primary

+972-9-747-1557

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FLO-ISR-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.